- Home
- MNPR
as 02-21-2025 4:00pm EST
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WILMETTE |
| Market Cap: | 250.0M | IPO Year: | 2019 |
| Target Price: | $43.00 | AVG Volume (30 days): | 70.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.72 - $54.30 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Monopar Therapeutics Inc. News
MNPR Breaking Stock News: Dive into MNPR Ticker-Specific Updates for Smart Investing
Insider Monkey
19 days ago
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025
PR Newswire
a month ago
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
TipRanks
a month ago
Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright
MT Newswires
a month ago
Piper Sandler Initiates Monopar Therapeutics at Overweight With $72 Price Target
Zacks
2 months ago
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
TipRanks
2 months ago
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025
Zacks
2 months ago
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
MT Newswires
2 months ago
Monopar Therapeutics Prices $40 Million Offering, Private Placement
Compare MNPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNPR Monopar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.